| pubmed-article:8381763 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8381763 | lifeskim:mentions | umls-concept:C0238033 | lld:lifeskim |
| pubmed-article:8381763 | lifeskim:mentions | umls-concept:C0007427 | lld:lifeskim |
| pubmed-article:8381763 | lifeskim:mentions | umls-concept:C0034804 | lld:lifeskim |
| pubmed-article:8381763 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:8381763 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:8381763 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:8381763 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:8381763 | pubmed:dateCreated | 1993-3-17 | lld:pubmed |
| pubmed-article:8381763 | pubmed:abstractText | Male breast cancer is probably hormone dependent, but studies are few due to the rarity of this tumor. We have studied 21 cases of male breast cancer immunohistologically for estrogen receptor (ER) and cathepsin D (CD) expression. In carcinoma of the female breast ER expression is associated with longer patient survival and responsiveness to hormonal manipulation. Cathepsin D is an estrogen-regulated lysosomal protease with proteolytic and mitogenic properties whose presence denotes a functioning ER. In our series of male breast carcinomas 86% were ER positive and 62% were CD positive; this compares with typical figures of 50% and 66%, respectively, for female breast cancer. We observed no trends between expression of ER and CD and patient survival; immunostaining for ER and CD is unlikely to be clinically useful in carcinoma of the male breast. The high rate of ER positivity in males suggests that male and female breast carcinomas are biologically different tumors. | lld:pubmed |
| pubmed-article:8381763 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8381763 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8381763 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8381763 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8381763 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8381763 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8381763 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:8381763 | pubmed:issn | 0046-8177 | lld:pubmed |
| pubmed-article:8381763 | pubmed:author | pubmed-author:RogersSS | lld:pubmed |
| pubmed-article:8381763 | pubmed:author | pubmed-author:DayC ACA | lld:pubmed |
| pubmed-article:8381763 | pubmed:author | pubmed-author:LEEF PFP | lld:pubmed |
| pubmed-article:8381763 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8381763 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:8381763 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8381763 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8381763 | pubmed:pagination | 148-51 | lld:pubmed |
| pubmed-article:8381763 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8381763 | pubmed:meshHeading | pubmed-meshheading:8381763-... | lld:pubmed |
| pubmed-article:8381763 | pubmed:meshHeading | pubmed-meshheading:8381763-... | lld:pubmed |
| pubmed-article:8381763 | pubmed:meshHeading | pubmed-meshheading:8381763-... | lld:pubmed |
| pubmed-article:8381763 | pubmed:meshHeading | pubmed-meshheading:8381763-... | lld:pubmed |
| pubmed-article:8381763 | pubmed:meshHeading | pubmed-meshheading:8381763-... | lld:pubmed |
| pubmed-article:8381763 | pubmed:meshHeading | pubmed-meshheading:8381763-... | lld:pubmed |
| pubmed-article:8381763 | pubmed:meshHeading | pubmed-meshheading:8381763-... | lld:pubmed |
| pubmed-article:8381763 | pubmed:meshHeading | pubmed-meshheading:8381763-... | lld:pubmed |
| pubmed-article:8381763 | pubmed:meshHeading | pubmed-meshheading:8381763-... | lld:pubmed |
| pubmed-article:8381763 | pubmed:meshHeading | pubmed-meshheading:8381763-... | lld:pubmed |
| pubmed-article:8381763 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8381763 | pubmed:articleTitle | Expression of cathepsin D and estrogen receptor in male breast carcinoma. | lld:pubmed |
| pubmed-article:8381763 | pubmed:affiliation | Department of Pathology, University of Sheffield Medical School, UK. | lld:pubmed |
| pubmed-article:8381763 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8381763 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8381763 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8381763 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8381763 | lld:pubmed |
